Abbott India Ltd
NSE: ABBOTINDIA BSE: 500488
₹27445
(1.26%)
Mon, 25 May 2026, 07:50 am
Market Cap590.61B
PE Ratio37.58
Dividend1.71
Health Technology
Pharmaceuticals: Major
24.5KAbbott India Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are well covered by earnings (2.6x coverage).
- Dividends per share have been stable in the past 10 years.
- Abbott India's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Abbott India's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Abbott India is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Abbott India is profitable, therefore cash runway is not a concern.
- Abbott India is profitable, therefore cash runway is not a concern.
- Abbott India has no debt, it does not need to be covered by operating cash flow.
- Abbott India has no debt, it does not need to be covered by short term assets.
- Abbott India's cash and other short term assets cover its long term commitments.
- Abbott India currently has no debt however we can't compare to 5 years ago as we have no data for that period.
- Abbott India has no debt, therefore coverage of interest payments is not a concern.
- Abbott India has no debt.
- High level of physical assets or inventory.
management
- The average tenure for the Abbott India board of directors is less than 3 years, this suggests a new board.
misc
- Abbott India is not covered by any analysts.
past
- Abbott India's 1-year earnings growth exceeds its 5-year average (31.6% vs 20.2%)
- Abbott India has delivered over 20% year on year earnings growth in the past 5 years.
- Abbott India used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Abbott India has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Abbott India's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (31.6% vs 22.7%).
- Abbott India's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
value
- ABBOTINDIA outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- ABBOTINDIA outperformed the Market in India which returned -14.5% over the past year.
- Abbott India's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Abbott India's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Abbott India is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Abbott India is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Abbott India is overvalued based on earnings compared to the India market.
- NSEI:ABBOTINDIA is down -9.1% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:ABBOTINDIA is down -9.1% underperforming the market in India which returned 8% over the past month.